Ocugen Inc
OCGN
NASDAQ
Biotechnology
$1.35
USD
0.00 (0.00%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $457.80M
Volume 3.0M
Revenue
$4.77M
TTM
+0.4%
YoY
Gross Margin
100%
TTM
0.0%
YoY
Net Income
$-81.81M
TTM
-43.7%
YoY
Operating Cash Flow
$-60.87M
TTM
-17.7%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Revenue | 1.4 | 1.8 | 0.0 | 1.5 | 1.5 |
YoY Growth | +20.3% | +54.2% | -100.0% | +3.5% | +8.4% |
Cost of Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross Profit | 1.4 | 1.8 | 0.0 | 1.5 | 1.5 |
Selling, General & Administrative | 6.8 | 8.2 | 0.0 | 8.1 | 7.2 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Operating Expenses | 15.2 | 19.4 | 0.0 | 19.4 | 17.9 |
Operating Income | -13.8 | -17.6 | 0.0 | -17.8 | -16.4 |
EBITDA | -12.6 | -16.7 | -0.4 | -17.2 | -15.9 |
Other Income / Expense | 0.1 | -1.3 | 0.0 | -0.2 | -4.4 |
Total Other Income / Expense | -0.9 | -2.4 | 0.0 | -1.3 | -8.4 |
Income Before Income Taxes | -14.7 | -20.1 | 0.0 | -19.2 | -24.9 |
Income Taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Net Income | -14.7 | -20.1 | -17.7 | -19.2 | -24.9 |
Consolidated Net Income / Loss | -14.7 | -20.1 | 0.0 | -19.2 | -24.9 |
Net Income Attributable to Common Shareholders | -14.7 | -20.1 | 0.0 | -19.2 | -24.9 |
Basic EPS | -$0.05 | -$0.07 | $0.00 | -$0.06 | -$0.07 |
Diluted EPS | -$0.05 | -$0.07 | $0.00 | -$0.06 | -$0.07 |
Basic Shares Outstanding | 292.1M | 304.0M | 312.6M | 327.5M | 338.7M |
Diluted Shares Outstanding | 292.1M | 304.0M | 312.6M | 327.5M | 338.7M |